TOSCA - pubblicazioni
Three Or Six Colon Adjuvant
A RANDOMIZED TRIAL INVESTIGATING THE ROLE OF FOLFOX-4 OR XELOX (3 VERSUS 6 MONTHS) REGIMEN DURATION AND BEVACIZUMAB AS ADJUVANT THERAPY FOR PATIENTS WITH STAGE II/III COLON CANCER
· OXALIPLATIN PLUS FLUOROPYRIMIDINES AS ADJUVANT THERAPY FOR COLON CANCER IN OLDER PATIENTS: A SUBGROUP ANALYSIS FROM THE TOSCA TRIAL
Scarica il file
· IMPACT OF THE IDEA IDEA COLLABORATION STUDY RESULTS ON CLINICAL PRACTICE IN FRANCE FOR PATIENTS WITH STAGE III COLON CANCER: A NATIONAL GERCOR - PRODIGE SURVEY.
Scarica il file
· DURATION OF ADJUVANT DOUBLET CHEMOTHERAPY (3 OR 6 MONTHS) IN PATIENTS WITH
HIGH-RISK STAGE II COLORECTAL CANCER
Scarica il file
· EFFECT OF DURATION OF ADJUVANT CHEMOTHERAPY FOR PATIENTS WITH STAGE III COLON
CANCER (IDEA COLLABORATION): FINAL RESULTS FORM A PROSPECTIVE, POOLED ANALYSIS OF SIX
RANDOMIZED, PHASE 3 TRIALS
Scarica il file
Scarica il file
· OVERALL SURVIVAL WITH 3 OR 6 MONTHS OF ADJUVANT CHEMOTHERAPY IN ITALIAN TOSCA
PHASE 3 RANDOMIZED TRIAL
Scarica il file
· LETTER COMMENT AND RESPONSE RISK-BENEFIT TOSCA
Scarica il file
· ASSESSMENT OF DURATION AND EFFECTS OF 3 VS 6 MONTHS OF ADJUVANT CHEMOTHERAPY IN
HIGH-RISK STAGE II COLORECTAL CANCER: A SUBGROUP ANALYSIS OF THE TOSCA RANDOMIZED
CLINICAL TRIAL
Scarica il file
· KHORANA SCORE AND THROMBOEMBOLIC RISK IN STAGE II - III COLORECTAL CANCER
PATIENTS: A POST HOC ANALYSIS FROM THE ADJUVANT TOSCA TRIAL
Scarica il file
· PREDICTIVE IMPACT OF MUCINOUS TUMORS ON THE CLINICAL OUTCOME IN PATIENTS
WITH POORLY DIFFERENTIATED, STAGE II COLON CANCER: A TOSCA SUBGROUP ANALYSIS
Scarica il file
· DURATION OF OXALIPLATIN - CONTAINING ADJUVANT.
THERAPY FOR STAGE III COLON CANCER: ASCO CLINICAL PRACTICE GUIDELINE
Scarica il file
· IMPACT OF METFORMIN USE AND DIABETIC STATUS DURING ADJUVANT FLUOROPYRIMIDINE -
OXALIPLATIN CHEMOTHERAPY ON THE OUTCOME OF PATIENTS WITH RESECTED COLON CANCER:
A TOSCA STUDY SUBANALYSIS
Scarica il file
· TOSCA IDEA: RIFLESSIONI E COMMENTI
Scarica il file
· FOLFOX OR CAPOX IN STAGE II TO III COLON CANCER: EFFICACY RESULTS OF THE ITALIAN THREE
OR SIX COLON ADJUVANT TRIAL
Scarica il file
· THE HARD ROAD TO DATA INTERPRETATION: THREE OR SIX MONTHS OF ADJUVANT
CHEMOTHERAPIE FOR PATIENTS WITH STAGE III COLON CANCER?
Scarica il file
· DURATION OF ADJUVANT CHEMOTHERAPY FOR STAGE III COLON CANCER
Scarica il file
· PHASE III TRIAL COMPARING 3-6 MONTHS OF ADJUVANT FOLFOX4/XELOX IN STAGE II-III COLON CANCER: SAFETY AND COMPLIANCE IN THE TOSCA TRIAL
Scarica il file
· GENETIC MARKERS FOR TOXICITY OD ADJUVANT OXALIPLATIN AND FLUOROPYRIMIDINES IN THE PHASE III TOSCA TRIAL IN HIGH-RISK COLON CANCER PATIENTS
Scarica il file
· DIHYDROPYRIMIDINE DEHYDROGENASE PHARMACOGENETICS FOR PREDICTING
FLUOROPYRIMIDINE-RELATED TOXICITY IN THE RANDOMIZED, PHASE III ADJUVANT TOSCA TRIAL
IN HIGH-RISK COLON CANCER PATIENTS
Scarica il file